Glaucoma surgery that when combined with cataract surgery, the IOP is reduced even further than when done alone. Long term (three year) results have been published both in the US and Europe demonstrating a significant and sustained reduction in both eye pressure and the number of glaucoma medications required for glaucoma control. Certain cells within the eye's ciliary body produce aqueous humor. A ciliary destructive or cyclodestructive procedure is one that aims to destroy those cells in order to reduce intraocular pressure. Cyclocryotherapy, or cyclocryopexy, uses a freezing probe. Cyclophotocoagulation, also known as transscleral cyclophotocoagulation, ciliary body ablation, cyclophotoablation, and cyclophototherapy, uses
Glaucoma valve drainage, such as iStent, CyPass, or Hydrus. A Cochrane Review of various aqueous shunts and modifications found that the Baerveldt implant may result in lower IOP than the Ahmed implant, but it was unclear if the difference in IOP reduction was clinically significant. The review suggests that practitioners should operate with the devices that they are most comfortable with, and have the most experience using. The glaucoma valve implant is indicated for glaucoma patients not responding to maximal medical therapy, with previous failed guarded filtering surgery (trabeculectomy) or in cases where conventional drainage surgery is unlikely to succeed. Common situations